Table 2.

Correlations between epidermal growth factor receptor (EGFR) and KRAS mutations or EGFR-tyrosine kinase inhibitor therapeutic efficacy and the anaplastic lymphoma kinase fusion gene

Feature	Total	Positive	Negative	P-value†
EGFR n(%) 103 (100)
Mutation	16 (15.5)	1 (2.6)	15 (23.1)	0.005
Wild	87 (84.5)	37 (97.4)	50 (76.9)
KRAS n(%) 103 (100)
Mutation	4 (3.9)	0 (0)	4 (6.2)	0.294
Wild	99 (96.1)	38 (100)	61 (93.8)
Time of benefiting from EGFR-TKI treatment n(%) 34 (100)
≤6 months	27 (79.4)	9 (100)	18 (72.0)	0.151
>6 months	7 (20.6)	0 (0)	7 (28.0)

^†Comparison between positive and negative groups. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.